LSTA1

Generic Name
LSTA1
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1392278-76-0
Unique Ingredient Identifier
Z8MXU5GH4Q
Associated Conditions
-
Associated Therapies
-

LSTA1 Phase 1b/2a Continuous Infusion Trial in MPDAC

First Posted Date
2024-09-19
Last Posted Date
2024-12-13
Lead Sponsor
Lisata Therapeutics, Inc.
Target Recruit Count
30
Registration Number
NCT06592664
Locations
🇺🇸

University of Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

Spartanburg Medical Center, Spartanburg, South Carolina, United States

and more 2 locations

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

First Posted Date
2023-02-03
Last Posted Date
2024-12-13
Lead Sponsor
Lisata Therapeutics, Inc.
Target Recruit Count
80
Registration Number
NCT05712356
Locations
🇪🇸

Hospital Universitario de Vinalopó, Elche, Alicante, Spain

🇪🇸

Hospital Universitario de Jerez, Jerez De La Frontera, Cadiz, Spain

🇪🇸

Start Madrid - Hospital Universitario HM Sanchinarro, Madrid, Spain

and more 23 locations

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

First Posted Date
2021-09-13
Last Posted Date
2024-10-22
Lead Sponsor
Australasian Gastro-Intestinal Trials Group
Target Recruit Count
158
Registration Number
NCT05042128
Locations
🇦🇺

Prince of Wales Hospital, Sydney, New South Wales, Australia

🇦🇺

Royal Brisbane and Womens Hospital, Herston, Queensland, Australia

🇦🇺

Flinders Medical Centre, Adelaide, South Australia, Australia

and more 21 locations
© Copyright 2024. All Rights Reserved by MedPath